Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
– NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up…
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology…
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program,…
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
SAN DIEGO–(BUSINESS WIRE)– Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…